BioMedPartners

Founded in 2017, TOLREMO therapeutics is a biotechnology company based in Muttenz, Switzerland. It specializes in developing small molecule therapies to target and eradicate cancer cells that cause drug resistance, aiming to prolong the lives of cancer patients.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Founded in 2017, TOLREMO therapeutics is a biotechnology company based in Muttenz, Switzerland. It specializes in developing small molecule therapies to target and eradicate cancer cells that cause drug resistance, aiming to prolong the lives of cancer patients.

Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.

Founded in 2017, TOLREMO therapeutics is a biotechnology company based in Muttenz, Switzerland. It specializes in developing small molecule therapies to target and eradicate cancer cells that cause drug resistance, aiming to prolong the lives of cancer patients.

Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.

Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.

Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, founded in 2001 by Francois Spertini. The company specializes in the discovery and development of allergy vaccines utilizing a proprietary technology known as Contiguous Overlapping Peptides, aimed at enabling ultra-fast desensitization for patients with allergies. Anergis offers immunotherapy solutions targeting common allergens such as birch pollen, ragweed pollen, and house dust mites. Their innovative approach focuses on providing disease-modifying treatments that seek to deliver long-term cures for allergies, ultimately reducing treatment time and improving the overall medical management of allergy sufferers.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, founded in 2001 by Francois Spertini. The company specializes in the discovery and development of allergy vaccines utilizing a proprietary technology known as Contiguous Overlapping Peptides, aimed at enabling ultra-fast desensitization for patients with allergies. Anergis offers immunotherapy solutions targeting common allergens such as birch pollen, ragweed pollen, and house dust mites. Their innovative approach focuses on providing disease-modifying treatments that seek to deliver long-term cures for allergies, ultimately reducing treatment time and improving the overall medical management of allergy sufferers.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, founded in 2001 by Francois Spertini. The company specializes in the discovery and development of allergy vaccines utilizing a proprietary technology known as Contiguous Overlapping Peptides, aimed at enabling ultra-fast desensitization for patients with allergies. Anergis offers immunotherapy solutions targeting common allergens such as birch pollen, ragweed pollen, and house dust mites. Their innovative approach focuses on providing disease-modifying treatments that seek to deliver long-term cures for allergies, ultimately reducing treatment time and improving the overall medical management of allergy sufferers.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.

Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, founded in 2001 by Francois Spertini. The company specializes in the discovery and development of allergy vaccines utilizing a proprietary technology known as Contiguous Overlapping Peptides, aimed at enabling ultra-fast desensitization for patients with allergies. Anergis offers immunotherapy solutions targeting common allergens such as birch pollen, ragweed pollen, and house dust mites. Their innovative approach focuses on providing disease-modifying treatments that seek to deliver long-term cures for allergies, ultimately reducing treatment time and improving the overall medical management of allergy sufferers.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of novel anti-infectives aimed at women's health. Founded in 2008, Lumavita focuses on addressing infections that affect women, with key products including FemiFect, an antibiotic designed to treat vaginitis caused by various pathogens, and SPK-601, which targets human papilloma virus (HPV) and herpes simplex virus (HSV). The company operates as a subsidiary of Shogoo Pharmaceuticals KK and distributes its products through a network of distributors. Lumavita AG was previously known as Shogoo Pharmaceuticals, AG before rebranding in 2007.

Idiag AG is a Swiss company that specializes in designing, manufacturing, and marketing healthcare equipment aimed at improving health and performance. Founded in 1993 and based in Fehraltorf, the company offers a range of products, including SpinalMouse for back assessments, STMedical for respiratory therapy, SpiroTiger for respiratory training, and the Biacorpus RX 4000 for body composition analysis. Additionally, Idiag provides solutions for weight management, spinal analysis, and therapy, catering to a diverse clientele that includes doctors, physiotherapists, medical personnel, and both professional and recreational athletes. The company focuses on converting innovative medical technology ideas into market-ready products, collaborating with universities and innovation centers for development and marketing. Idiag markets its products through dealers in Switzerland, Germany, and other international markets, leveraging its resources and networks for effective sales and market penetration.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Okairos AG is a biopharmaceutical company headquartered in Basel, Switzerland, with operations in Rome and Naples, Italy. The company specializes in the discovery and development of genetic T-cell vaccines, focusing on conditions such as hepatitis C virus. Okairos also excels in gene delivery technologies, providing expertise in scalable viral-vector manufacturing processes. This enables other biotech firms to transition genetic vaccines and medicinal products from preclinical stages to commercial readiness, utilizing advanced good manufacturing practice (GMP) facilities. Previously a subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Okairos is dedicated to advancing innovative therapeutic solutions in the healthcare sector.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to developing and marketing innovative treatments for mitochondrial and neuromuscular diseases, areas with significant unmet medical needs.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

4-Antibody AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of human antibody therapeutics with a focus on immuno-oncology. Founded in 2002, the company utilizes its proprietary Retrocyte Display technology, which generates therapeutic antibody drug candidates from human antibody libraries expressed in mammalian B-lineage lymphocytes. In addition to providing its drug discovery platform to pharmaceutical partners, 4-Antibody is actively developing a pipeline of preclinical antibody programs targeting various immune checkpoints, including GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.